Literature DB >> 16777580

Assessments in ankylosing spondylitis.

Jane Zochling1, Jürgen Braun, Désirée van der Heijde.   

Abstract

Assessment of disease status and response to therapy in ankylosing spondylitis is a rapidly expanding area of research. The assessment in ankylosing spondylitis international working group has contributed greatly to this development, defining core sets of health domains for use in daily practice and in clinical trials, developing and validating measurement instruments corresponding to these health domains, and developing response and remission criteria for use in clinical trials. This chapter reviews available measures of three major areas of disease impact in ankylosing spondylitis (disease activity, structural damage and functioning), and discusses which measures are relevant for use in clinical practice.

Entities:  

Mesh:

Year:  2006        PMID: 16777580     DOI: 10.1016/j.berh.2006.03.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  16 in total

1.  [Epionics SPINE-use of an objective method to examine spinal mobility in patients with axial spondyloarthritis].

Authors:  D Kiefer; X Baraliakos; B Bühring; U Kiltz; J Braun
Journal:  Z Rheumatol       Date:  2020-03       Impact factor: 1.372

2.  New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey.

Authors:  Shervin Assassi; Michael H Weisman; MinJae Lee; Laurie Savage; Laura Diekman; Tiffany A Graham; Mohammad H Rahbar; Joan I Schall; Lianne S Gensler; Atul A Deodhar; Daniel O Clegg; Robert A Colbert; John D Reveille
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

3.  Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.

Authors:  Ashit Syngle; Kanchan Vohra; Anjali Sharma; L Kaur
Journal:  Clin Rheumatol       Date:  2010-03-05       Impact factor: 2.980

4.  A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis.

Authors:  Muhammet Cinar; Sedat Yilmaz; Fatma Ilknur Cinar; Suleyman Serdar Koca; Hakan Erdem; Salih Pay; Ayhan Dinc; Yusuf Yazici; Ismail Simsek
Journal:  Rheumatol Int       Date:  2015-03-21       Impact factor: 2.631

5.  Fatigue in patients with spondyloarthritis associates with disease activity, quality of life and inflammatory bowel symptoms.

Authors:  Simon M Stebbings; Gareth J Treharne; Katey Jenks; John Highton
Journal:  Clin Rheumatol       Date:  2013-12-10       Impact factor: 2.980

Review 6.  Appropriate management of axial spondyloarthritis.

Authors:  Sean P LaSalle; Atul A Deodhar
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

7.  Spironolactone improves endothelial dysfunction in ankylosing spondylitis.

Authors:  Ashit Syngle; Kanchan Vohra; Dinesh Khichi; Nidhi Garg; Inderjeet Verma; Ladbans Kaur
Journal:  Clin Rheumatol       Date:  2013-03-16       Impact factor: 2.980

Review 8.  Treat-to-target in axial spondyloarthritis - what about physical function and activity?

Authors:  Jürgen Braun; Xenofon Baraliakos; Uta Kiltz
Journal:  Nat Rev Rheumatol       Date:  2021-07-26       Impact factor: 20.543

9.  The relationship between disease activity measured by the BASDAI and psychological status, stressful life events, and sleep quality in ankylosing spondylitis.

Authors:  Yutong Jiang; Mingcan Yang; Husheng Wu; Hui Song; Feng Zhan; Shengyun Liu; Guanmin Gao; Zhangsuo Liu; Zhaoxian Hu; Peigen He; Shengtao Zhang; Zaiying Hu; Zhiming Lin; Yanli Zhang; Yinong Li; Lingxun Shen; Anbing Huang; Zetao Liao; Shuangyan Cao; Yanlin Wei; Li Li; Qiuxia Li; Qing Lv; Jun Qi; Jianlin Huang; Tianwang Li; O Jin; Yunfeng Pan; J Gu
Journal:  Clin Rheumatol       Date:  2014-06-20       Impact factor: 2.980

10.  Responsiveness to therapy change of a global ultrasound assessment in spondyloarthritis patients.

Authors:  Santiago Ruta; María Laura Acosta Felquer; Javier Rosa; David A Navarta; Ricardo García Monaco; Enrique R Soriano
Journal:  Clin Rheumatol       Date:  2014-05-20       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.